Heat submits new trial plan for lung-cancer drug

Heat Biologics (HTBX +0.2%) has submitted a revised protocol with the FDA for the Phase II trial of the company's HS-110 drug for the treatment of non-small cell lung cancer (NSCLC).

HS-110 utilizes genetically modified lung-cancer cells to stimulate a patient's immune system against a wide array of lung-cancer antigens.

Heat plans to start the study in Q3 and enroll 120 patient. The endpoints will include overall survival rates. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs